Latest Ratios: P/E Ratio -49.0x · EV/EBITDA N/A · ROE N/A. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $1.1B | $136M | $269M | $128M | $281M | $402M | — | — | — | — |
| Enterprise Value | $1.4B | $1.1B | $137M | $244M | $140M | $243M | $332M | — | — | — | — |
| P/E Ratio → | -49.02 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 41.84 | 37.30 | — | 7.42 | 26.78 | 106.29 | 173.06 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 10.50 | 5.71 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 38.73 | — | 6.74 | 29.25 | 91.97 | 142.88 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -36.5% | -36.5% | 951.2% | -74.0% | -977.8% | -1986.4% | -1566.8% | -1841.0% | -864.2% | -678.9% | -403.1% |
| Net Profit Margin | -80.8% | -80.8% | 947.6% | -109.6% | -1194.3% | -1775.7% | -1444.7% | -2003.7% | -872.2% | -702.4% | -403.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -96.7% | -98.0% | -825.6% | -104.3% | -85.3% | -132.6% |
| ROA | -35.5% | -35.5% | -84.5% | -51.7% | -70.6% | -39.9% | -35.3% | -99.4% | -58.5% | -59.5% | -77.0% |
| ROIC | — | — | — | — | — | — | -698.8% | -1153.3% | — | -1099.7% | -628.4% |
| ROCE | -115.5% | -115.5% | -260.5% | -81.3% | -107.7% | -58.4% | -46.5% | -122.4% | -72.7% | -71.9% | -105.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 1.72 | 0.70 | — | 1.44 | 0.11 | 0.33 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -1.41 | -1.00 | — | -1.10 | -0.97 | -0.88 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.30 | -1.30 | -8.44 | -3.04 | -7.83 | -67.43 | -109.96 | -9.76 | -35.50 | -233.15 | -213.84 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | 1.09 | 1.04 | 1.75 | 1.38 | 2.53 | 6.58 | 3.22 | 3.68 | 5.68 | 3.26 |
| Quick Ratio | 1.09 | 1.09 | 1.04 | 1.75 | 1.30 | 2.53 | 6.58 | 3.03 | 3.58 | 6.20 | 3.87 |
| Cash Ratio | 0.92 | 0.92 | 0.84 | 1.51 | 1.09 | 2.28 | 6.26 | 2.45 | 3.12 | 5.05 | 2.55 |
| Asset Turnover | — | 0.44 | -0.11 | 0.39 | 0.08 | 0.03 | 0.02 | 0.05 | 0.08 | 0.06 | 0.18 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 94.57 | -433.28 | 29.91 | 217.20 | 537.02 | 608.36 | 180.42 | 104.60 | 82.77 | 0.35 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $48M | $47M | $37M | $35M | $35M | $24M | $22M | $20M | $17M | $15M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBTX stock.
Nanobiotix S.A.'s current P/E ratio is -49.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Nanobiotix S.A. is trading at a P/E of -49.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nanobiotix S.A. has 100.0% gross margin and -36.5% operating margin.
Key Metrics
Top Statement Risk
Milestone-dependent revenue concentration
Multiples Reflect Milestone Optionality, Not Earnings
According to the supplied market data, NBTX trades at a P/S of 46.71 and a negative trailing P/E of -54.73, a configuration that suggests investors are pricing future partner-linked milestones rather than current earnings power.
A 46.71 price-to-sales multiple against a revenue base that swings from roughly $33M to negative quarters appears to rest on expectations of future clinical success rather than on sustained revenue generation. The negative P/E is uninformative in isolation because net losses persist, so the more useful reading is that equity value depends on the NANORAY-312 readout and the durability of the Janssen relationship. Investors should monitor whether the multiple compresses as revenue normalizes, since a high P/S on lumpy partner income may not be sustainable if milestone recognition slows.
Full Gross Margin Masks Operating Losses
Based on the reported figures, NBTX shows a 100% gross margin across all ten quarters, yet its operating margin of -3.2% in 2026Q2 and net margin of -6.3% indicate that development spending absorbs the entire licensing contribution.
The uniform 100% gross margin reflects licensing economics with no reported cost of goods sold, so it carries little information about future manufacturing profitability. Operating margins have oscillated between roughly +3.0% and -19.5% without a durable inflection, which suggests earnings quality is governed by milestone timing rather than an improving cost base. Net margin deterioration to -80.8% on a TTM basis versus the quarterly figures indicates non-operating charges that warrant further investigation.
Negative Equity Constrains Refinancing Flexibility
As reported in financial statements, NBTX's debt-to-equity ratio of 25.17 in 2022Q2 and total debt of $106.6M against negative equity of -$33.4M in 2026Q2 suggest a balance sheet where liabilities materially exceed the equity cushion.
Negative shareholder equity means that any impairment or further losses directly erode a position already offset by liabilities, leaving limited margin for repayment or refinancing. Interest coverage is negative in most periods, indicating that operating income does not currently cover financing costs, which appears to heighten dependence on partner payments or equity issuance. Investors should monitor debt maturities and any covenant terms, as these are not detailed in the supplied data and their absence limits conclusions about near-term refinancing risk.
Cash Buffer Thin Against Persistent Burn
Based on EDBL-style reported figures, NBTX's current ratio of 1.44 and cash of $110.8M in 2026Q2 provide a near-term buffer, but cash has ranged from $21.6M to $83.9M across the window, indicating reliance on lumpy inflows.
The current ratio is supported by cash and deferred revenue recognition rather than by a self-funding operating model, so headline liquidity can overstate the cushion available under stress. Because the quick ratio equals the current ratio, inventory dependence is negligible, and the relevant stress test is cash runway against quarterly burn of roughly $22M to $23M in operating and free cash flow. A severe revenue pause from partners would likely compress the buffer quickly, warranting monitoring of cash balances against burn.
Revenue Growth May Overstate Commercial Traction
Based on reported figures, the 512.3% year-over-year revenue growth and 100% gross margin could be misread as commercial traction, while the swinging quarterly pattern suggests the revenue base is non-recurring and partner-dependent.
Trailing P/S and gross margin metrics are most commonly misapplied to this business model because they imply a product-sales economy that does not exist here. Gross margin is structurally uninformative under licensing revenue recognition, so the more relevant measure is operating cash burn relative to milestone timing. Investors should adjust for milestone and upfront-payment recognition and model a revenue cliff if partner payments do not recur.